NO995036L - 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer - Google Patents

5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer

Info

Publication number
NO995036L
NO995036L NO995036A NO995036A NO995036L NO 995036 L NO995036 L NO 995036L NO 995036 A NO995036 A NO 995036A NO 995036 A NO995036 A NO 995036A NO 995036 L NO995036 L NO 995036L
Authority
NO
Norway
Prior art keywords
heterocyclyl
heteroaryl
aryl
compound
lower alkyl
Prior art date
Application number
NO995036A
Other languages
English (en)
Other versions
NO995036D0 (no
Inventor
Shripad S Bhagwat
Chih-Hung Lee
Marlon D Cowart
Jeffrey Mckie
Anne Laure Grillot
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO995036L publication Critical patent/NO995036L/no
Publication of NO995036D0 publication Critical patent/NO995036D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

En metode for å inhibere adenosinkinase ved å administrere en forbindelse som har formelen hvori R1 og R2 er uavhengig valgt fra H, lavere alkyl, Cj-CjalkoksyCj-Cealkyl, aryl-C^-C,;.alkyl, -C (O) Cj-Cjalkyl, -C(O)aryl, -C(O)heterocyklyl eller kan forbindes med nitrogenet som de er bundet til, og danner en 5-7- leddet ring eventuelt inneholdende 1-2 ytterligere heteroatomer valgt fra O, N eller S; R3 er valgt fra gruppen bestående av lavere alkyl, lavere alkenyl, 2,avere alkynyl, cykloalkyl, aryl, arylalkyl, hetero- aryl, heterocyklyl, heteroarylalkyl eller heterocyklo- alkyl hvor heteroaryl- og heterocyklylgruppene er bundet direkte eller indirekte av et ringkarbonatom; R* er valgt fra gruppen bestående av lavere alkyl, lavere alkenyl, lavere alkynyl, cykloalkyl, aryl, arylalkyl, heteroaryl, heterocyklylheteroarylalkyl eller hetero- cykloalkyl; og en stiplet linje --- indikerer at en dobbeltbinding er eventuelt nærværende forutsatt at de riktige valenser opprettholdes, en farmasøytisk sammen- setning omfattende en terapeutisk effektiv mengde av en forbindelse som definert ovenfor i kombinasjon med en farmasøytisk akseptabel bærer, og en metode for å behandle cerebral iskemi, epilepsi, nocipersepsjon, inflammasjon og sepsis i et pattedyr i behov av slik behandling, omfattende å administrere til pattedyret en terapeutisk effektiv mengde av en forbindelse som definert ovenfor, en fremgangsmåte for å fremstille nevnte forbindelser, og forbindelser som har ovennevnte formel.
NO995036A 1997-04-16 1999-10-15 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer NO995036D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
PCT/US1998/007207 WO1998046605A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO995036L true NO995036L (no) 1999-10-15
NO995036D0 NO995036D0 (no) 1999-10-15

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995036A NO995036D0 (no) 1997-04-16 1999-10-15 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer

Country Status (18)

Country Link
EP (1) EP0989986A1 (no)
JP (1) JP2001520655A (no)
KR (1) KR20010006509A (no)
CN (1) CN1252070A (no)
AR (1) AR012436A1 (no)
AU (1) AU7108398A (no)
BG (1) BG103842A (no)
BR (1) BR9809055A (no)
CA (1) CA2286909A1 (no)
CO (1) CO4940446A1 (no)
HU (1) HUP0001434A3 (no)
IL (1) IL131618A0 (no)
NO (1) NO995036D0 (no)
PL (1) PL336304A1 (no)
SK (1) SK141799A3 (no)
TR (1) TR199902455T2 (no)
WO (1) WO1998046605A1 (no)
ZA (1) ZA983177B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
DE10335183A1 (de) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
CN101243081A (zh) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
KR20080080395A (ko) * 2005-12-21 2008-09-03 아보트 러보러터리즈 항바이러스 화합물
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2009029632A1 (en) * 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
MX2010002098A (es) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Compuesto policiclico.
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
CN102333777B (zh) * 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
CN110256420B (zh) * 2019-05-07 2020-04-28 江西中医药大学 四氢吡啶并嘧啶衍生物及其制备方法和用途
CN110283171A (zh) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
HUP0001434A3 (en) 2001-01-29
WO1998046605A1 (en) 1998-10-22
EP0989986A1 (en) 2000-04-05
CA2286909A1 (en) 1998-10-22
CO4940446A1 (es) 2000-07-24
CN1252070A (zh) 2000-05-03
PL336304A1 (en) 2000-06-19
ZA983177B (en) 1999-01-22
NO995036D0 (no) 1999-10-15
BG103842A (en) 2000-06-30
AU7108398A (en) 1998-11-11
SK141799A3 (en) 2000-08-14
HUP0001434A2 (hu) 2000-10-28
BR9809055A (pt) 2000-08-08
TR199902455T2 (xx) 2000-01-21
KR20010006509A (ko) 2001-01-26
AR012436A1 (es) 2000-10-18
JP2001520655A (ja) 2001-10-30
IL131618A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
NO995036L (no) 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
EP3122747B1 (en) Dihydropyrimidine compounds and their application in pharmaceuticals
CA2876690C (en) Dihydropyrimidine compounds and their application in pharmaceuticals
CA2927373C (en) Processes for preparing dihydropyrimidine derivatives and intermediates thereof
HUP0100348A2 (hu) Hattagú, egy vagy két nitrogénatomot tartalmazó kondenzál biciklusok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények, valamint intermedierek
AR063351A1 (es) DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA.
NO20072115L (no) Farmasoytiske forbindelser
KR20090079257A (ko) 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11b-헥사히드로-2H-피리도[2,1-a]이소퀴놀린-2-올 화합물 및 그와 관련된 방법
EP2597087A1 (en) Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
CN114206339A (zh) 氘化mk2途径抑制剂及其使用方法
NO20060650L (no) Kinazolinderivater som angiogeneseinhibitorer
CO5540385A2 (es) Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen
CA2942599A1 (en) N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl] amides
NO179974C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser
CA2042113A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FI104070B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridiini- ja imidatsolijohdannaisten valmistamiseksi
SK164397A3 (en) Method for preparing n-monosubstituted and n,n'-disubstituted unsymmetrical cyclic ureas
IL95250A (en) 1-) Pyridinylamino (-2-pyrolidinones, a process for their preparation and use as drugs
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
KR20010023890A (ko) 항비루스제로서의 퓨린 아시클로뉴클레오시드류
CN111417635B (zh) 具有抗呼吸道合胞病毒(rsv)活性的吡唑并嘧啶
NO995033L (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
WO2023160572A1 (zh) 吡唑类衍生物、药物组合物及应用
NO995035L (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3- D]pyrimidinforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application